Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?. Leukemia. 2024;38:1156–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv. 2017;1:288–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial. Transpl Cell Ther. 2023;29:208.e1–208.e6.

CAS  Google Scholar 

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7:e100–e111.

Article  PubMed  Google Scholar 

Arcuri LJ, Kerbauy MN, Kerbauy LN, de Santos FPS, Ribeiro AAF, Hamerschlak N. ATG in HLA-matched, peripheral blood, hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a secondary analysis of a CIBMTR database. Transplant Cell Ther. 2023;29:40.e1–40.e4.

Article  CAS  PubMed  Google Scholar 

Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389–96.

Article  CAS  PubMed  Google Scholar 

Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kröger N, et al. Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors–an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2025;60:1574–83.

Article  CAS  PubMed  Google Scholar 

Devillier R, Labopin M, Chevallier P, Ledoux M-P, Socié G, Huynh A, et al. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplant. 2018;53:431–7.

Article  CAS  PubMed  Google Scholar 

Mohty M, Malard F. Antithymocyte globulin for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3993–5.

Article  PubMed  Google Scholar 

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132–e143.

Article  PubMed  PubMed Central  Google Scholar 

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.

Article  PubMed  PubMed Central  Google Scholar 

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147–e159.

Article  CAS  PubMed  Google Scholar 

Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14:31.

Article  PubMed  PubMed Central  Google Scholar 

Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MW, van Roessel C, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023;203:439–45.

Article  CAS  PubMed  Google Scholar 

Chalandon Y, Eikema D-J, Moiseev I, Ciceri F, Koster L, Vydra J, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv. 2024;8:4792–802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023;129:3735–45.

Article  CAS  PubMed  Google Scholar 

Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.

Article  PubMed  PubMed Central  Google Scholar 

Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griskevicius L, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024;59:1012–21.

Article  CAS  PubMed  Google Scholar 

Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87.

Article  PubMed  PubMed Central  Google Scholar 

Battipaglia G, Labopin M, Hamladji R-M, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209–18.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

CAS  PubMed  Google Scholar 

Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.

Article  CAS  PubMed  Google Scholar 

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

Article  Google Scholar 

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin. N Engl J Med. 2025;393:243–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonifazi F, Rubio M-T, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55:1093–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al. PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025;9:660–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9.